Experimental evaluation of vitellogenin as a predictive biomarker for reproductive disruption.
Vitellogenin (VTG) synthesis in male oviparous vertebrates is used as an indicator of environmental estrogen exposure, but the relationship between elevated VTG levels and the effects of environmental estrogens on reproductive success are poorly understood. To examine whether altered VTG expression predicts reproductive impairment, we exposed medaka (Oryzias latipes) for 2 or 8 weeks posthatch to 0, 0.5, 1.0, 2.5, and 7.5 ppb of the environmental estrogen o,p'-DDT. Fish were sampled 2, 4, and 8 weeks after hatch to examine VTG expression and gonad development. After exposure, fish were transferred to clean water, grown to sexual maturity, and placed in mating pairs. We collected eggs for 7 days and scored them for fecundity (number of eggs), fertility (percent fertilized), and hatching success (percent hatched). DDT had no effect on VTG expression after a 2-week exposure, whereas all doses induced VTG after 8 weeks. At both exposure durations, the highest doses of DDT caused a female-skewed sex ratio in adults. Gonadal feminization appeared to be progressive: some ovotestes were observed after 2- or 4-week exposure to the two highest doses, but the proportion of ovaries increased after 8 weeks. Both 2- and 8-week exposures significantly reduced fertility and hatching success at all doses, with lower doses having a greater effect after longer exposure. Fertility and hatching success were more sensitive to estrogenic disruption than were gonad differentiation and vitellogenin expression. We suggest that VTG expression may be interpreted as a warning of reproductive consequences, but absence of expression cannot be interpreted as absence of consequences.
Cheek
A O
AO
Department of Biological Sciences, Southeastern Louisiana University, Hammond, LA 70402, USA. acheek@selu.edu
Brouwer
T H
TH
Carroll
S
S
Manning
S
S
McLachlan
J A
JA
Brouwer
M
M
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D003634:DDT / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004625:Embryo, Nonmammalian / Q000187:drug effects; D047108:Embryonic Development; D004968:Estrogens, Non-Steroidal / Q000009:adverse effects*; D005260:Female; D005298:Fertility / Q000187:drug effects*; D008297:Male; D012744:Sex Ratio; D012741:Sexual Maturation / Q000187:drug effects*; D014818:Vitellogenesis / Q000187:drug effects; D014819:Vitellogenins / Q000032:analysis / Q000096:biosynthesis*
D015415:Biomarkers; D004968:Estrogens, Non-Steroidal; D014819:Vitellogenins; D003634:DDT; C016340:o,p'-DDT